BridgeBio Pharma
BBIO
359 hedge funds and large institutions have $8.15B invested in BridgeBio Pharma in 2025 Q2 according to their latest regulatory filings, with 92 funds opening new positions, 136 increasing their positions, 105 reducing their positions, and 34 closing their positions.
388% more call options, than puts
Call options by funds: $515M | Put options by funds: $105M
171% more first-time investments, than exits
New positions opened: 92 | Existing positions closed: 34
30% more repeat investments, than reductions
Existing positions increased: 136 | Existing positions reduced: 105
26% more capital invested
Capital invested by funds: $6.45B → $8.15B (+$1.71B)
18% more funds holding
Funds holding: 304 → 359 (+55)
1.42% more ownership
Funds ownership: 98.02% → 99.44% (+1.4%)
6% less funds holding in top 10
Funds holding in top 10: 18 → 17 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$78.9M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$76.6M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$72.9M |
| 4 |
D.E. Shaw & Co
New York
|
+$72.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$57.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KKRC
Kohlberg Kravis Roberts & Co
New York
|
-$218M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$127M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$94.5M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$69.1M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$28M |
BBIO Hedge Fund Activity: Q2 2025 in Review
359 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q2 2025, worth a combined $8.15B — up 26% from $6.45B a quarter earlier.
Buyers outnumbered sellers: 92 funds opened new BBIO positions and 34 closed out — a net gain of 58 holders — while 136 added to existing stakes and 105 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $78.9M. The largest seller was Kohlberg Kravis Roberts & Co, cutting an estimated $218M.
- 359 institutional investors held BridgeBio Pharma (BBIO) as of Q2 2025, up from 304 in Q1 2025.
- Funds reported $8.15B of BridgeBio Pharma stock for Q2 2025, up 26% quarter-over-quarter.
- 92 funds opened new BridgeBio Pharma positions in Q2 2025 and 34 closed out, a net change of +58 holders.
- The largest BridgeBio Pharma buyer in Q2 2025 was Farallon Capital Management, an estimated $78.9M added.
- The largest BridgeBio Pharma seller in Q2 2025 was Kohlberg Kravis Roberts & Co, an estimated $218M sold.
Based on aggregated 13F filings for Q2 2025.